← Back to All US Stocks

RDNT Stock Analysis 2026 - RadNet, Inc. AI Rating

RDNT Nasdaq Services-Medical Laboratories DE CIK: 0000790526
Recently Updated • Analysis: Apr 8, 2026 • SEC Data: 2025-12-31
SELL
78% Conf
Pending
Analysis scheduled

📊 RDNT Key Takeaways

Revenue: $2.0B
Net Margin: -0.9%
Free Cash Flow: $224.7M
Current Ratio: 1.76x
Debt/Equity: 1.00x
EPS: $-0.25
AI Rating: SELL with 78% confidence

Is RDNT a Good Investment? Thesis Analysis

Claude

RadNet demonstrates revenue growth of 11.5% YoY but is plagued by deteriorating profitability with net income declining 209% YoY and operating margins compressing to just 3%. The critical concern is an interest coverage ratio of 0.9x, indicating the company cannot cover debt obligations from operating income, creating unsustainable leverage given the $1.1B debt load and negative net margins.

Why Buy RDNT? Key Strengths

Claude
  • + Strong free cash flow generation of $224.7M (11% FCF margin)
  • + Solid revenue growth of 11.5% YoY demonstrates market demand
  • + Healthy liquidity with current ratio of 1.76x and $767.2M cash balance

RDNT Investment Risks to Consider

Claude
  • ! Unprofitable operations with -0.9% net margin and -$18.7M net income
  • ! Interest coverage ratio of 0.9x indicates inability to service debt from operations
  • ! Severe earnings deterioration with -209% YoY net income decline and -725% EPS decline
  • ! High leverage (1.00x D/E) unsustainable for unprofitable company facing margin compression

Key Metrics to Watch

Claude
  • * Path to profitability and operating margin recovery
  • * Interest coverage ratio improvement above 1.5x threshold
  • * Debt reduction progress and leverage normalization

RDNT Financial Metrics

Revenue
$2.0B
Net Income
$-18.7M
EPS (Diluted)
$-0.25
Free Cash Flow
$224.7M
Total Assets
$3.8B
Cash Position
$767.2M

💡 AI Analyst Insight

RadNet, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.

RDNT Profitability Ratios

Gross Margin N/A
Operating Margin 3.0%
Net Margin -0.9%
ROE -1.7%
ROA -0.5%
FCF Margin 11.0%

RDNT vs Healthcare Sector

How RadNet, Inc. compares to Healthcare sector averages

Net Margin
RDNT -0.9%
vs
Sector Avg 12.0%
RDNT Sector
ROE
RDNT -1.7%
vs
Sector Avg 15.0%
RDNT Sector
Current Ratio
RDNT 1.8x
vs
Sector Avg 2.0x
RDNT Sector
Debt/Equity
RDNT 1.0x
vs
Sector Avg 0.6x
RDNT Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is RDNT Overvalued or Undervalued?

Based on fundamental analysis, RadNet, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.

Return on Equity
-1.7%
Sector avg: 15%
Net Profit Margin
-0.9%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
1.00x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

RDNT Balance Sheet & Liquidity

Current Ratio
1.76x
Quick Ratio
1.76x
Debt/Equity
1.00x
Debt/Assets
63.9%
Interest Coverage
0.89x
Long-term Debt
$1.1B

RDNT 5-Year Financial Trend & Growth Analysis

RDNT 5-year financial data: Year 2021: Revenue $1.3B, Net Income $14.8M, EPS $0.29. Year 2022: Revenue $1.4B, Net Income -$14.8M, EPS $-0.29. Year 2023: Revenue $1.6B, Net Income $24.7M, EPS $0.46. Year 2024: Revenue $1.8B, Net Income $10.7M, EPS $0.17. Year 2025: Revenue $2.0B, Net Income $3.0M, EPS $0.05.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: RadNet, Inc.'s revenue has grown significantly by 55% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.05 reflects profitable operations.

RDNT Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
11.0%
Free cash flow / Revenue

RDNT Quarterly Performance

Quarterly financial performance data for RadNet, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $461.1M -$2.6M $-0.04
Q2 2025 $459.7M -$3.0M $-0.04
Q1 2025 $431.7M -$2.8M $-0.04
Q3 2024 $402.0M -$2.6M $-0.04
Q2 2024 $403.7M -$3.0M $-0.04
Q1 2024 $390.6M -$2.8M $-0.04
Q3 2023 $350.0M $668.0K $0.01
Q2 2023 $354.4M $7.9M $0.12

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

RDNT Capital Allocation

Operating Cash Flow
$298.8M
Cash generated from operations
Capital Expenditures
$74.2M
Investment in assets
Dividends Paid
$759.0K
Returned to shareholders

RDNT SEC 10-K & 10-Q Filing Analysis

Access official SEC EDGAR filings for RadNet, Inc. (CIK: 0000790526)

📋 Recent SEC Filings

Date Form Document Action
Mar 23, 2026 4 xslF345X06/ownership.xml View →
Mar 18, 2026 4 xslF345X06/ownership.xml View →
Mar 12, 2026 4 xslF345X05/ownership.xml View →
Mar 5, 2026 4 xslF345X05/ownership.xml View →
Mar 5, 2026 4 xslF345X05/ownership.xml View →

Frequently Asked Questions about RDNT

What is the AI rating for RDNT?

RadNet, Inc. (RDNT) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.

What are RDNT's key strengths?

Claude: Strong free cash flow generation of $224.7M (11% FCF margin). Solid revenue growth of 11.5% YoY demonstrates market demand.

What are the risks of investing in RDNT?

Claude: Unprofitable operations with -0.9% net margin and -$18.7M net income. Interest coverage ratio of 0.9x indicates inability to service debt from operations.

What is RDNT's revenue and growth?

RadNet, Inc. reported revenue of $2.0B.

Does RDNT pay dividends?

RadNet, Inc. pays dividends, with $0.8M distributed to shareholders in the trailing twelve months.

Where can I find RDNT SEC filings?

Official SEC filings for RadNet, Inc. (CIK: 0000790526) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is RDNT's EPS?

RadNet, Inc. has a diluted EPS of $-0.25.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is RDNT a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, RadNet, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is RDNT stock overvalued or undervalued?

Valuation metrics for RDNT: ROE of -1.7% (sector avg: 15%), net margin of -0.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy RDNT stock in 2026?

Our dual AI analysis gives RadNet, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is RDNT's free cash flow?

RadNet, Inc.'s operating cash flow is $298.8M, with capital expenditures of $74.2M. FCF margin is 11.0%.

How does RDNT compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -0.9% (avg: 12%), ROE -1.7% (avg: 15%), current ratio 1.76 (avg: 2).

Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 8, 2026 | Data as of: 2025-12-31 | Powered by Claude AI